Shen_2021_Hepatol.Commun__

The pandemic of coronavirus disease 2019 (COVID-19) has become a global health crisis with the death toll of over 14 million people. So far, there are limited options to treat COVID-19. Remdesivir was granted emergency use authorization earlier, and full use recently. Remdesivir was originally developed against Ebola viral infection and has since been shown to exert a broad antiviral activity against as many as seven viral families [1]. On the other hand, serious adverse events and mortality remained high even with remdesivir among COVID-19 patients [2-4].